title: Association between renal injury and reduced interleukin-15 and interleukin-15 receptor levels in acute kidney injury.
abstract: Interleukin (IL)-15 serves as a survival factor for a broad array of cells. Renal cells express both IL-15 and its receptor (IL-15R); however, the role of IL-15 in the kidney is yet to be determined. We examined IL-15 and IL-15R levels in sepsis-related renal injury, ischemia-reperfusion injury (IRI), and cisplatin-induced nephrotoxicity. To test the anti-apoptotic effect of IL-15, Bcl-2/Bax mRNA levels were assessed in kidneys of IL-15Ralpha(-/-) mice and in IL-15-stimulated renal epithelial cells (RECs). In addition, RECs were exposed to cisplatin and apoptosis was evaluated by TUNEL staining, caspase-3 activity, and cell cycle analysis. Intrarenal IL-15 levels decreased 24 h after initiation of all three examined pathologies by 5.8-fold (sepsis), 11-fold (IRI), and 23-fold (cisplatin-induced nephrotoxicity). Further experiments revealed that while addition of rIL-15 (1 ng/mL) to wild-type (WT) RECs increased Bcl-2/Bax ratio by 2-fold, kidneys of IL-15Ralpha(-/-) mice exhibited 4-fold lower Bcl-2/Bax ratio compared to WT mice. Accordingly, IL-15 lowered the apoptotic rate in cisplatin-treated cultured REC, and IL-15Ralpha(-/-) renal cells exhibited a higher rate of cisplatin-induced apoptosis. Furthermore, IL-15 levels negatively correlated with BUN of cisplatin-treated mice (R = -0.69, P = 0.003), suggesting that a decline in renal-derived IL-15 is detrimental to renal cell survival and kidney function during pathological stress.
authors: Clinical Biochemistry Department, Ben-Gurion University of the Negev, Beer-Sheva, Israel.
authors: Hadar
authors: H
authors: Eini
authors: Noa
authors: N
authors: Tejman-Yarden
authors: Eli C
authors: EC
authors: Lewis
authors: Cidio
authors: C
authors: Chaimovitz
authors: Moshe
authors: M
authors: Zlotnik
authors: Amos
authors: A
authors: Douvdevani
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D053148:Caspase 3 / Q000378:metabolism; D002478:Cells, Cultured; D002945:Cisplatin / Q000633:toxicity; D004847:Epithelial Cells / Q000187:drug effects / Q000276:immunology / Q000378:metabolism* / Q000473:pathology; D019409:Interleukin-15 / Q000235:genetics / Q000378:metabolism*; D007674:Kidney Diseases / Q000209:etiology / Q000378:metabolism* / Q000473:pathology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000378:metabolism*; D053647:Receptors, Interleukin-15 / Q000235:genetics / Q000378:metabolism*; D015427:Reperfusion Injury / Q000378:metabolism*; D018805:Sepsis / Q000150:complications / Q000276:immunology
chemical_list: D019409:Interleukin-15; D019253:Proto-Oncogene Proteins c-bcl-2; D053647:Receptors, Interleukin-15; D053148:Caspase 3; D002945:Cisplatin